Clinical trials: acne
Acne Vulgaris
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.
- Trial name
- NCT01209949
- Testing
- Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age.
- Trial name
- NCT07863193
- Testing
- Denifanstat
- Where
- 28 sites in United States
- Volunteers
- 800 people
- Sponsor
- Sagimet Biosciences Inc.
Acne Vulgaris, Atrophic Acne Scars
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
This was a multi-centre, randomized, investigator blinded, vehicle controlled trial using intra-individual comparison (right half-face versus left half-face).
- Trial name
- OSCAR (NCT02735421)
- Testing
- ABPO Forte Gel, Vehicle gel
- Where
- 7 sites in Canada, France
- Volunteers
- 67 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
This is a 12 week, multi-site, double-blind, vehicle-controlled study in subjects with mild to moderate facial acne. Subjects will be randomized 1:1 to apply either topical NAG or vehicle gel daily.
- Trial name
- NCT02404285
- Testing
- Next Science Acne Gel, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Next Science TM
Acne Vulgaris
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
- Trial name
- NCT00660985
- Testing
- Adapalene
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris
The objective of this study was to evaluate the efficacy and safety of the test formulation of adapalene gel 0.1% (PLIVA Research \& Development Ltd.) as compared to the already marketed formulation, Differin® (adapalene 0.1%)…
- Trial name
- NCT01182636
- Testing
- Adapalene, Differin®
- Where
- 22 sites in United States, Belize
- Volunteers
- 601 people
- Sponsor
- Teva Pharmaceuticals USA
Hidradenitis Suppurativa
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens…
- Trial name
- NCT04179175
- Testing
- secukinumab
- Where
- 191 sites in United States, Argentina and 36 more
- Volunteers
- 702 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER (OLE) (NCT01635764)
- Testing
- adalimumab
- Volunteers
- 508 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Acne Vulgaris, Acneiform Eruptions
The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne
The purpose of this study is to evaluates how probiotics and dietary supplementation with an herbal powder can shift the gut microbiome in those with non-cystic acne vulgaris.
- Conditions
- Acne Vulgaris, Acneiform Eruptions, Skin Diseases, Sebaceous Gland Diseases
- Trial name
- NCT05919810
- Testing
- Probiotic, Oral herbal powder supplement
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Acne Vulgaris
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in Subjects with acne vulgaris after a 12-week…
- Trial name
- NCT00441415
- Testing
- Adapalene BPO
- Where
- 4 sites in United States
- Volunteers
- 272 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate
The purpose of this study is to determine the safety and efficacy of association between tretinoin and clindamycin phosphate on the treatment of acne vulgaris mild and moderate.
- Trial name
- NCT00838812
- Testing
- application of the topic gel
- Where
- Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Igefarma Laboratorios S.A.
Acne Vulgaris
A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.
Evaluate patient preference factors comparing two clindamycin/benzoyl peroxide gels. One dispensed in a pump presentation, the other in a tube presentation.
- Trial name
- NCT00377000
- Testing
- clindamycin 1% / benzoyl peroxide 5% gel pump, clindamycin 1% / benzoyl peroxide 5% tube
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acne Vulgaris
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12.
- Trial name
- NCT00422240
- Testing
- Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%
- Where
- United States
- Volunteers
- 1,668 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety.
- Trial name
- NCT02578043
- Testing
- Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%, Onexton™ Gel
- Volunteers
- 844 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne…
- Trial name
- NCT02886715
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Where
- 25 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Acne Vulgaris
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
- Trial name
- NCT03168334
- Testing
- IDP-123 Lotion, IDP-123 Vehicle Lotion
- Where
- 45 sites in United States, Canada
- Volunteers
- 801 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams…
- Trial name
- NCT02160678
- Testing
- Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%
- Where
- United States
- Volunteers
- 1,741 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Acne Vulgaris
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01095640
- Testing
- adapalene 0.3% topical gel
- Where
- India
- Volunteers
- 1,159 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne…
- Trial name
- AKLIEF (NCT07186413)
- Testing
- Trifarotene, Vehicle Cream
- Where
- China
- Volunteers
- 561 people
- Sponsor
- Galderma R&D